Sibylla Biotech
Bresso, Italy · sibyllabiotech.it
On your own
Free. Their own email.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
Sibylla Biotech develops small-molecule drug candidates using a folding-interference approach to target proteins before they become undruggable. It focuses on drug discovery and preclinical development for oncology and other disease areas from its sites in Bresso, Italy.
They take quote requests by email.
What they offer
Drug discovery and development
Develops small-molecule drug candidates through a protein-folding interference approach from hit identification through preclinical drug discovery.
PPI-FIT platform
Uses Pharmacological Protein Inactivation by Folding Intermediate Targeting to identify folding intermediates and design small-molecule degraders.
Oneiros AI Platform
Applies machine learning to binding site identification, hit discovery, optimization, and prioritization of compounds.
Folding simulations
Uses physics-based protein folding simulation to investigate folding intermediates and guide target selection and ligand design.
Preclinical evaluation
Advances pipeline programs through preclinical evaluation.
What they work on
- Modalities
- Small molecule
- Species and models
- cellular prion protein (PrP), cell surface glycoprotein
- Assays and studies
- binding site identification, hit discovery, hit optimization, preclinical drug discovery
- Therapeutic areas
- oncology, central nervous system disorders, cancer indications, prion diseases
- Sites
- Bresso, Italy · Verona, Italy
- Serves
- worldwide
Public records
- Ownership
- SIBYLLA BIOTECH S.P.A. · IT GLEIF
Similar labs. Atavistik Bio, Aurigene Pharmaceutical Services, Canthera Discovery, Evotec
Found in a contract services directory. Listing built from sibyllabiotech.it. Work here? Claim this listing.